Clinical Trial Recruitment: A Study of Autologous TCR-T Cell Therapy LioCyx-M for Safety and Efficacy in Advanced Hepatocellular Carcinoma

Jun 07, 2024 15:45 CST Updated 15:45

Lion TCR

Developer of Novel Immunotherapies

Clinical Recruitment for Advanced Hepatocellular Carcinoma

Dear Volunteer Friends:

Beijing GaoBo BoRen Hospital will conduct a clinical study on the safety and efficacy of autologous TCR-T cell LioCyx-M in the treatment of advanced hepatocellular carcinoma. This study has been reviewed and approved by the hospital’s ethics committee and is now openly recruiting participants from the public. Relevant information regarding this clinical study is as follows:

Highlights:

Academician Wang Fusheng's Team: The World's First Specific TCR-T Cell Therapy Targeting HBV Antigen Shows Initial Promise in Advanced Liver Cancer!

Laien Bio Announces Over 300 Million Yuan in Series B2 Financing, Globally Leading mRNA-Encoded TCR-T Cell Therapy for Solid Tumors

About Laien Bio

Lion TCR is a clinical-stage biotechnology company focused on TCR therapy. The company has proactively utilized mRNA to encode TCR for use in clinical trials treating liver cancer, demonstrating good safety and significant efficacy. Through an AI-powered TCR discovery platform, the company expands targets and indications, providing innovative therapies for unresolved clinical issues. Meanwhile, the companyAlreadyThe layout includes autologous cell therapy, and the off-the-shelf therapy product platform encompasses in vivo TCR-T therapy delivered via mRNA-LNP, among others.

LIONTCR

WeChat ID｜Laien Bio

Official Website｜https://www.liontcr.com/